Pfizer

2Q Revenues: $11.7 billion (+3%)

2Q Earnings: $2.4 billion (-30%)*

YTD Revenues: $23.5 billion (flat)

YTD Earnings: $6.5 billion (+73%)**

Comments: Lipitor, Celebrex, Geodon and Lyrica performed well in the quarter: Lipitor sales were up 9% to $3.1 billion; Celebrex sales were $471 million, up 17%; Geodon sales were up 14% to $165 million and Lyrica sales were $271 million, up 38%. The company received approval/launched four products: Zeven, Eraxis, Exubera, and Chantix.

*Results for the quarter includes an impairment charge of $1.2 billion related to the developed technology rights and the write-off of machinery and equipment for Bextra. Results also include a merger-related in-process R&D expense write-off of $513 million related to the acquisition of Rinat Neurosciences Corp.

**YTD earnings include the tax provision related to the repatriation of foreign earnings of $1.7 billion. Results reflect the sale of the Consumer Healthcare business to Johnson & Johnson for approximately $16.6 billion, as discontinued operations.